Correction: Swedish Indian businessman Prashant Agarwal participates in the share issue as top underwriter
Scandinavian ChemoTech announced in a press release on September 23, at 15:39, that Prashant Agarwal will participate as top underwriter, with the sum of SEK 500,000 should the issue be oversubscribed. The Company is now correcting this announcement.
The preamble of the press release should have stated the following:
Through his company, businessman Prashant Agarwal has signed an agreement to be top underwriter in ChemoTech's new rights issue of units. The guaranteed sum amounts to SEK 500,000, which he wishes to subscribe to regardless of whether the Company's issue is oversubscribed or not. In the event that it is oversubscribed, the board will allocate units to Ajna Holding in accordance with the oversubscription clause communicated in the terms and conditions.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
ir@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
